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Subcutaneous calciﬁcationAbstract Objective: Juvenile dermatomyositis (JDM) is the most common inﬂammatory myopa-
thy of childhood and is characterized by proximal muscle weakness and pathognomonic skin
rashes. In this study, we performed a descriptive cross sectional study to assess the clinical manifes-
tations and outcomes of 39 patients with JDM from the northeast of Iran during 12 years and com-
pared our ﬁndings with other studies.
Design: 39 patients (16 boys and 23 girls) with juvenile dermatomyositis were studied retrospec-
tively between 2001 and 2013. Gender, age at disease onset and diagnosis, clinical manifestations,
laboratory data at onset, treatment and outcome of these patients were reviewed.
Measurements and results: The mean age of onset was 9.42 ± 3.85 years. At the time of presenta-
tion, muscle weakness occurred in 100%; heliotrope rash in 51.2%; gottron’s papules in 46.1%, cal-
cinosis in 12.8%, and 87.1% had at least one abnormal muscle enzyme result. Muscle biopsy was
performed in 15.3% and was abnormal in all. All patients received corticosteroids; but methotrex-
ate, hydroxychloroquine, intravenous immunoglobulin, or azathioprine was added to corticosteroid
in some patients. The mean follow-up period was 22.66 ± 23.53 months.
Conclusions: This study was in parallel with other reviews except for calcinosis which was observed
with lower frequency. It is suggested that delay in diagnosis and treatment may be associated with
calcinosis.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Pediatric Association.Introduction
Juvenile dermatomyositis (JDM) is a rare, potentially life-
threatening systemic autoimmune disease primarily affectingmuscle and skin.1 It has some extramuscular manifestations
such as joint contractures, dysphagia, cardiac disturbances,
pulmonary symptoms, and subcutaneous calciﬁcations.2 Cuta-
neous ﬁndings are often the ﬁrst manifestation, allowing early
diagnosis of the disease.3
The incidence of JDM is estimated in 2 to 3 cases per
million populations.2,3 The diagnosis of this entity is difﬁcult
and often delayed due to its rarity and this is a major factor
for poor prognosis.2 The diagnosis is conﬁrmed when patients
prove to meet Bohan and Peter’s diagnostic criteria4,5 namely
symmetric muscle weakness, increased muscle enzymes,
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ﬁndings on muscle biopsy, and characteristic dermatologic
signs. These ﬁve criteria are applicable to its diagnosis,
although their sensitivity and speciﬁcity have not been vali-
dated in children but are probably 45–90% and 90%, respec-
tively. The deﬁnite diagnosis of JDM requires the presence
of the pathognomonic rash and three of the four mentioned
criteria.6
As JDM is a very rare disease in the world and it was not
evaluated in Iran so far, we decided to perform this study in
this geographic area and review the characteristic of JDM in
cohort of thirty nine patients from multicentral referral hospi-
tals of the northeast of Iran over a period of 12 years and com-
pare our patients’ characteristics with other studies.
Patients and methods
In this descriptive cross sectional study, we reviewed the
records of 39 patients diagnosed as having JDM according
to Bohan and Peter’s diagnostic criteria4,5 in the rheumatology
units of referral teaching hospitals of the Mashhad University
of Medical Sciences located in the northeast of Iran between
July 2001 and January 2013. Inclusion criteria were age at
disease onset equal to or less than16 years and patients with
characteristic rash and weakness within 6 months. Exclusion
criteria were age more than 16 years, diagnosis of other myop-
athy (inﬂammatory or non inﬂammatory) such as muscle
dystrophies, endocrine problems that can affect the muscles,
history of using corticosteroids or medications that can cause
myopathy or myositis, muscle weakness without characteristic
skin rash of JDM.
We ﬁlled data sheets with the following data of JDM
patients’ ﬁles that had been referred to rheumatology clinics
of our university referral hospitals or admitted there. These
included age, sex, duration of disease, evaluation of muscle
weakness, whether rash or muscle weakness (or both) was
the ﬁrst symptom, the interval between disease onset and initial
treatment, electrophysiological study ﬁndings, presence of
extramuscular manifestations such as arthritis, dysphagia,
cardiac disturbance, pulmonary symptoms, subcutaneous
calciﬁcations, and associated disorders such as overlap, mixed
connective tissue disease, juvenile idiopathic arthritis, systemic
lupus erythematosus, malignancy and also follow-up duration
was recorded.
Laboratory ﬁndings such as creatine kinase (CK), alanine
and aspartate aminotransferase (ALT, AST), antinuclear anti-
bodies (ANA), rheumatoid factor (RF), electromyograghy and
muscle biopsy were analyzed.
Follow-up of the patients had been performed at 1–3 month
intervals. We assessed their muscle strength, skin rashes and
their laboratory data such as inﬂammatory parameters and
muscle enzymes in accordance with patients’ ﬁles. Evaluation
of outcomes had been performed on all patients except 8
patients who did not return after discharge from hospital and
we only found their admission data and data before hospitaliza-
tion, when they visit a rheumatologist in clinic. The outcomes
of juvenile DM patients during the evaluation period were
deﬁned as (1) remission: disappearance of skin manifesta-
tions, normalization of muscle strength, normal function of
major organs, normalization of both serum muscle enzyme
levels and electromyographic abnormalities after therapydiscontinuation; (2) improvement: improvement of muscle
strength and skin manifestations, functions of involved major
organs, and biochemical data with therapy; (3) deterioration:
worsening of muscle strength and skin manifestations, func-
tions of involved major organs, and biochemical ﬁndings
despite therapy, and (4) death: death of patient despite therapy
during the follow-up period.
Descriptive analysis of demographic data, clinical features
and treatment variables were reported by correspondent abso-
lute and percentual frequencies. Quantitative variables were
described by median and range.
Results
Our study included 39 JDM patients, 16 boys and 23 girls, with
a mean age of 9.42 ± 3.85 years and sex-ratio of (M/F) 1:1.4.
Age of onset was variable from 3–15 years. The mean duration
of the disease before diagnosis was 3.33 ± 3.32 months. The
mean follow-up duration was 22.66 ± 23.53 months (ranging
from 1 to 90 months). Of the 39 children, 33 patients had def-
inite JDM and 6 had probable disease.
Constitutional signs and symptoms
Fever in the range of 38 C to 40 C was observed in 16/39
(41.02%) patients but it was not the reason for the ﬁrst presen-
tation. All patients showed fatigue, malaise and anorexia.
Early fatigue as a ﬁrst presentation was noticed in 32/39
(82.05%) patients.
Musculoskeletal manifestation
Muscle weakness was the ﬁrst symptom in 29/39 (74.3%)
cases. Within 3 months, all patients (100%) showed symmetri-
cal proximal muscle weakness. Seventeen (43.5%) patients had
myalgia. Neck ﬂexor muscle weakness was noticed in 3/39
(7.6%) patients, pharyngeal muscle weakness and dysphagia
were noticed in 12 (30.7%) of the patients which were con-
ﬁrmed by the Barium swallow study. None of the patients
showed facial, extra-ocular or neck extensor muscle weakness.
Within the ﬁrst 4 months of JDM diagnosis, arthritis and
arthralgia were developed in 19 (48.7%) and 13 (33.3%) of
the patients respectively. Arthritis in the knee was noticed in
10 (25.6%), ankle in 4 (10.2%), wrist in 5 (12.8%), elbow in
6 (15.38%) and metacarpophalangeal, metatarsophalangeal
and proximal interphalangeal joints in 4 (10.2%) patients.
Mucocutaneous manifestations
The ﬁrst clinical manifestation was cutaneous in 35 (89.7%)
patients, and within 1–3 months after the ﬁrst presentation,
rash was seen in all patients. Dermatological signs were dom-
inated by heliotrope rash in 20 (51.2%), gottron’s papules in 18
(46.15%) and nonspeciﬁc rashes including photosensitive rash,
located over the neck (V sign) and shoulders (shawl sign), skin
lesions on the ﬁngers (periungual erythema, nail-fold telangiec-
tasias), livedo reticularis and palpable purpura in 20 (51.3%)
of the patients. Two patients had livedo reticularis, palpable
purpura and skin ulcer and two had periungual and palmar
erythema and Raynaud’s phenomenon. Skin biopsy of these
Figure 1 The percentage of different cutaneous manifestations of 39 patients with juvenile dermatomyositis.
48 M. Saghaﬁ et al.patients showed vasculitis. In 9 (23.07%) patients, rashes
appeared ﬁrst and both rashes and muscle weakness were
noted ﬁrst in 26 (66.6%) cases. Fig. 1 shows different cutane-
ous manifestations in these patients.
The percentage of the patients in whose case both rashes
and weakness appeared ﬁrst was 26 (66.6%).
Calcinosis was detected in 5/39 (12.8%) patients (3 boys
and two girls). In 4 patients calcinosis appeared 3 years after
the diagnosis of JDM. Three of them had calcinosis in the sub-
cutaneous tissue of knees; one had calcinosis in the subcutane-
ous tissue of the knees, elbows and the deep tissue of the hip
region, which was detected by radiography. The last patient
presented with calcinosis in the subcutaneous tissue of the
elbow which was ulcerated and infected, 4 years after the diag-
nosis. In these ﬁve patients, the mean interval between the
development of the disease and diagnosis was 10 months, com-
pared to 3 months in children who had no calcinosis.
Extramuscular manifestations
Auxiliary lymphadenopathy was detected in 5 (12.8%)
patients. In two patients ﬁne reticulonodular pattern was
reported in chest radiography, but they did not display any
respiratory symptoms. Pulmonary function test showed a mild
restrictive pattern. Cardiac involvement was not observed in
our patients.Figure 2 The percentage of different clinical features of 39 patieIn one patient, the disease began with fever, gottron’s pap-
ules, periungual and palmar erythema, muscle weakness,
arthralgia in shoulders, arthritis in both knees and ankles
and morning stiffness. With the diagnosis of JDM, treatment
with prednisolone was started. Despite this treatment for
5 months and improvement in myositis, the arthritis was con-
tinued and the overlap of juvenile idiopathic arthritis and
juvenile dermatomyositis was diagnosed. Another patient
presented with photosensitivity, oral ulcer, malar rash, helio-
trope rash and gottron’s papules, vasculitis, hemolytic anemia
with positive coombs test, positive ANA and high titer of
anti-dsDNA and myositis, who was diagnosed with the over-
lap of systemic lupus erythematosus (SLE) and juvenile der-
matomyositis. One patient, 2.5 years after the diagnosis of
JDM, presented with photosensitivity, proteinuria and a rise
in anti-dsDNA titer [391U (<100)], who was also diagnosed
with the overlap of SLE and JDM. None of the patients
showed mixed connective tissue disease, scleroderma or
malignancy.
Fig. 2 demonstrates the percentage of different clinical fea-
tures of these patients at the time of presentation.
Laboratory ﬁndings
Muscle enzymes increased in 34 (87.1%) of the patients (84.6%
for creatinine phosphokinase and 82% for other enzymes).nts with juvenile dermatomyositis at the time of presentation.
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12.8% of the patients.
Electromyography was performed for all patients, which
revealed a myogenic tracing in 87.17% of the cases. Because
of incomplete criteria in 6 (15.3%) patients, muscle biopsy
was done in these patients and biopsy of all of them showed
inﬂammatory inﬁltrates including interstitial or perivascular
mononuclear cells together with degeneration, necrosis and
regeneration of myocytes.
Treatment and follow-up
For all the patients treatment was started with a daily prednis-
olone dose of 1–2 mg/kg. The dose was decreased after
4–6 weeks depending on the degree of clinical improvement
and side effects of the drug. The dose of prednisolone was
reduced by almost 10–20% of the initial dose every 1–2 weeks,
with a subsequent slower rate of reduction to one daily dose.
Oral methotrexate (5–15 mg/week) or azathioprine (2–3 mg/kg)
was started in combination with prednisolone in 9 patients
who had inadequate improvement in muscle strength, persis-
tence of elevated serum levels of muscle enzymes in response
to a closely monitored glucocorticoid program or glucocorti-
coid dependence, overlap of JDM and JIA or SLE and vascu-
litis. Hydroxychloroquine with a dose of 6 mg/kg/day was
added if the patient presented with extensive skin rash and
needed to take high dose steroids or had overlap of JDM
and SLE. For two patients intravenous gammaglobulin (IVIG)
was administered because they were steroid resistant and had
refractory arthritis. These patients exhibited a good response
at follow-up points. Rehabilitation and muscle strengthening
exercises were recommended for most of the patients.
Calcinosis was treated in two patients by surgical excision
because of the severity and its bad location but it relapsed in
one and surgical excision was performed again. In three, med-
ical treatment such as bisphosphonate and calcium channel
blockers was started. However they did not respond and the
result had been disappointing.
The median follow-up duration of our patients was
22.66 ± 23.53 months. Of these 39 patients, 21 (53.8%) had
remission, 10 (25.6%) had partial improvement and 8 patients
did not show up again to the rheumatology clinic after being
discharged from hospital. None of these 31 patients died
during the follow-up.
In three patients, there was an interval between the ﬁrst
symptoms and diagnosis. This delay was observed in those
where muscle weakness was the ﬁrst presenting complaint
because this symptom was often unnoticed or ignored at ﬁrst.Discussion
Juvenile dermatomyositis is a multi-system disease character-
ized by vasculopathy of the skin and/or muscles causing
subacute (over several weeks to months), progressive, proximal
muscle weakness and typical skin rashes.6,7 It is at least 10–20
times more common than polymyositis in children8 and tends
to have a more acute and severe onset.7,8
It is known that DM has a bimodal age distribution: one
peak occurs between 5–14 years of age and a second larger
peak occurs between 45–64 years of age.9,10 In our report,
the age at the onset of the disease was similar to other seriesof juvenile DM.11,12 It is reported that females outnumber
males by 2:1,9,10 and our study also showed a female
predominance.
Within the ﬁrst 4 months of diagnosis 33.3% of the children
in our study reported arthralgia and 48.7% showed arthritis
that is similar to other studies.6–8 Arthralgia and arthritis in
JDM is transient and nondeforming, sometimes accompanied
by tenosynovitis or ﬂexor contractures.6 Early development
of ﬂexion contractures is common and usually represents the
effects of muscle inﬂammation rather than synovitis.6 In our
study one patient had chronic arthritis despite the remission
of dermatomyositis which could be due to an overlap with
juvenile idiopathic arthritis.
It is important to recognize the skin manifestation of JDM
because it facilitates earlier diagnosis. Pachman et al., in a
study on 166 patients found that skin rash is the ﬁrst observed
manifestation in 65%.13 In our study, most patients with juve-
nile DM showed rashes and proximal muscle weakness within
4 months with the rash preceding muscle weakness in 23.07%
of them.
Calcinosis of the skin or muscle is rarely observed in adults,
but may occur in up to 40% of children or adolescents with
DM.14 In our study, subcutaneous calciﬁcations were found
in only 5 of our patients (12.8%) which were lower than those
found in previous studies7,15,16 but like other studies,8 delay in
diagnosis was associated with calcinosis in these children. This
extramuscular manifestation is particularly difﬁcult to treat
and studies are aimed at attempts to elucidate predictors.17
Interstitial lung disease (ILD) is often associated with
considerable morbidity and mortality in JDM. Asymptomatic
pulmonary involvement may occur in up to 50% of chil-
dren.6,18 Interstitial pneumonitis is rare and may be refractory
to treatment.6,18 In our study, interstitial pneumonitis was
found in two patients without any clinical symptoms.
Clinical features of our 39 patients with JDM are compared
with those in three other studies in Table 1.7,15,16
Malignancy is more common in dermatomyositis and with
older patients (>50 yr) and rare in childhood.19 In our study,
malignancy was not observed in any of the patients.
In laboratory ﬁndings, the rise in the muscle enzymes in our
patients was variable. CPK was not elevated in 15.4% of the
patients. Although this may be due to taking glucocorticoids
before admission, but the ﬁndings emphasize the importance
of complete enzymatic proﬁle in the diagnosis of JDM.
Glucocorticotherapy was the main treatment that our
patients received, which resulted in signiﬁcant improvement
in many patients. There are few prospective studies about
immunosuppressants effect in JDM.3 In our study immuno-
suppressants were added to corticosteroids in severe and resis-
tant cases and those with overlap and special problems
including vasculitis.
Mortality in inﬂammatory myopathy appears to be inﬂu-
enced by age, race, and sex. Children with inﬂammatory myo-
sitis, for instance, have a low mortality rate.8 In this study, we
also did not encounter any mortality within the follow-up
period.
Several studies have evaluated the short and long term
outcomes of DM.20–24 We observed that 53.8% of juvenile
DM patients achieved remission whereas 25.6% partially
improved and no patient was bedridden. Our ﬁndings are com-
patible with other studies showing DM remission rates varying
from 25% to 70%.2,7,25,26
Table 1 Demographic and frequency of clinical manifestations of juvenile dermatomyositis in four studies in different international
areas.
Parameter Present study (2013) Shehata et al. 7 (1999) Pachman et al. 15 (1998) Kishi et al. 16 (2012)
Area of study Iran Saudi Arabia USA Japan
Number of patients 39 25 79 50
Age range (year) 3–15 1.5–15 1.4–17 1.1–14.7
Mean age (year) 9.42 8.25 6.9 6.9
Duration of the study (year) 12 8 3 25
Male to female ratio 1:1.4 1.5:1 1:2.29 1:2.6
Proximal muscle weakness (%) 100 100 100 90
Muscle pain or tenderness (%) 43.5 52 73 90
Rash (%) 100 100 100 Not stated
Gottron’s papules (%) 46.1 60 Not stated 86
Heliotrope rash (%) 51.2 52 Not stated 80
Fever (%) 41.02 52 44 70
Arthralgia (%) 33.3 64 Not stated Not stated
Arthritis (%) 48.7 60 23 Not stated
Dysphagia (%) 30.7 32 43 Not stated
Calcinosis (%) 12.8 40 23 26
50 M. Saghaﬁ et al.In conclusion, the study of our 39 juvenile patients with
dermatomyositis with a mean follow up of 22.6 months
revealed that the occurrence rate of calcinosis was less than
several previous studies. With early and proper treatment,
the outcome of the disease was relatively favorable in most
of our patients.
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